Live Breaking News & Updates on Arvinas communications
Stay updated with breaking news from Arvinas communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Arvinas (NASDAQ:ARVN – Get Free Report) had its price target decreased by analysts at Barclays from $70.00 to $39.00 in a report released on Tuesday, FlyOnTheWall reports. Barclays‘s price objective points to a potential upside of 60.49% from the company’s previous close. Separately, Stifel Nicolaus cut their price target on shares of Arvinas from $75.00 […]
Arvinas (NASDAQ:ARVN – Get Free Report) is scheduled to be issuing its quarterly earnings data on Wednesday, August 2nd. Arvinas (NASDAQ:ARVN – Get Free Report) last released its earnings results on Friday, May 5th. The company reported ($1.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.05). The company had […]
Rossmore Private Capital lowered its position in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 56.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,322 shares of the company’s stock after selling 18,817 shares during the period. Rossmore Private Capital’s […]
Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 2,830,000 shares, an increase of 6.4% from the June 15th total of 2,660,000 shares. Approximately 6.2% of the shares of the company are short […]
NEW HAVEN, Conn., June 15, 2023 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon,... | June 15, 2023
05.06.2023 - NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two ...
Finepoint Capital LP raised its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Get Rating) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 429,600 shares of the company’s stock after buying an additional 30,600 shares during the quarter. Arvinas comprises […]
Arvinas, Inc. (NASDAQ:ARVN – Get Rating) hit a new 52-week low during trading on Tuesday . The stock traded as low as $21.86 and last traded at $22.00, with a volume of 64854 shares trading hands. The stock had previously closed at $22.79. Wall Street Analyst Weigh In ARVN has been the topic of a […]
Tekla Capital Management LLC lessened its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN – Get Rating) by 50.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 42,998 shares of the company’s stock after selling 42,999 shares during the period. […]
Shares of Arvinas, Inc. (NASDAQ:ARVN – Get Rating) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $22.07 and last traded at $22.17, with a volume of 115720 shares. The stock had previously closed at $23.20. Analyst Ratings Changes Several analysts have recently weighed in on ARVN […]